Vanguard Global Advisers’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
Other funds holding RYTM
BBA
Vanguard Global Advisers's RYTM Position: Q3 2026 in Review
Vanguard Global Advisers increased its Rhythm Pharmaceuticals (RYTM) stake by 2.3% in Q3 2026, buying an estimated $57.8K and bringing the position to 24,196 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1155.
Vanguard Global Advisers first reported a position in RYTM in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.63M in Q2 2026. 334 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.
- Vanguard Global Advisers held 24,196 shares of Rhythm Pharmaceuticals worth $2.3M as of Q3 2026.
- Vanguard Global Advisers bought 542 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $57.8K.
- Rhythm Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1155 holding.
- Vanguard Global Advisers first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Rhythm Pharmaceuticals position peaked at $2.63M in Q2 2026.
- 334 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.